Would you consider neoadjuvant immunotherapy prior to radiation for a locally advanced skin squamous cell carcinoma?

While the definitive trials are yet outstanding and enrollment in NRG HN0014 (NCT06568172) should be encouraged where it is open, the present indications for using cemiplimab should follow its principal indication, unresectable cutaneous squamous cell cancer, a minority of cases at 5%. Practically s...

Yes. I have done it for cases that are unresectable or the patient refuses surgery. For example, the PNI of a named nerve. At least 2 cycles, but we often give more to get maximum response. Depends on the response and if there were clinically positive nodes, but I have omitted elective nodal radiati...

This is an ever-increasing paradigm that is being adopted with little real data behind it. It is a question that arises in almost every tumor board. As has been stated, the data we have is mostly extrapolation from the phase II trial of 79 patients who had immunotherapy followed by surgery (Gross et...